If you’re eyeing Novavax (NVAX) today, you’re not alone, and the reason is clear. Investors are buzzing after the company announced a refinancing deal that pushes out most of its convertible debt from ...

Novavax has experienced a significant decline in its stock price, dropping by 19.26% over the past week. This downturn comes despite recent positive developments, including a $175 million milestone ...

Although infection prevention is an essential part of every rheumatologist’s routine, balancing efficacy, risk and individual patient choices — all while contending with a seemingly constant flow of ...

Novavax slid Thursday in its worst session in more than four months after laying out plans to refinance $225 million of debt, ...

Novavax (NVAX) downgraded to Underperform by BofA due to uncertain growth outlook despite cost-cutting measures. Read more ...

Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company focused on recombinant protein-based vaccines using nanoparticle and ...

“We’ve stepped back into the world that we lived in before the [CDC’s vaccine advisory committee] was created,” said Dr.

Drastic changes are brewing at the FDA, as newly appointed Commissioner Dr. Marty Makary indicates a shift toward stricter scientific accountability in vaccine approvals. In a notable departure from ...

The U.S. Food and Drug Administration may not renew its authorization for Pfizer's COVID-19 vaccine approved for children ...

The move would add another barrier for parents who want to vaccinate healthy children ahead of the respiratory virus season.

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

Last month, Novavax touted the Phase III efficacy of its flu-COVID combo but has decided to pause work on that vaccine until it can find a development partner. The company’s COVID-19 vaccine partner ...